CYDY

0.22202.97%
SM

Stephen M. Simes

Independent Director

Mr. Stephen M. Simes serves as Independent Director at CytoDyn Inc. since October 13, 2022. He also serves as a Director of BioLife4D Corporation, a private company developing a patient-specific, fully functioning human heart using 3D bioprinting and the patient’s own cells and currently preparing for an IPO. He is also Chairman of the Board of Bio-XL Limited, an Israeli company developing products in oncology. He serves as an advisor for SmartHealth Catalyzer and advises several emerging companies in varied therapeutic areas, including oncology and cardiology. He served as the Chief Executive Officer of Restorgenex Corporation (formerly, Stratus Media Group, Inc.) from March 5, 2014 to January 8, 2016. Mr. Simes served as the President of BioSante Pharmaceuticals, Inc., from January 1998 to June 2013 and served as-Chief Executive Officer since March 1998. Mr. Simes serves as an Advisor and Consultant to biopharma companies. He served as Chief Executive Officer and President of ANI Pharmaceuticals, Inc., until June 19, 2014. He served as the President and Chief Executive Officer of Unimed Pharmaceuticals Inc. from October 1994 to January 1997. From 1989 to 1993, he served as Chairman, President and Chief Executive Officer of Gynex Pharmaceuticals, Inc. From 1993 to 1994, he served as Senior Vice President of Savient Pharmaceuticals Inc. (formerly, Bio-Technology General Corp.). Since 1984, he has specialized in emerging companies, building product portfolios in endocrinology, urology, hormones and drug delivery systems, among other areas. Mr. Simes is a Member of the Ops Team of SmartHealth Activator. Mr. Simes serves on the advisory Board for NeuroLucent. His career in the pharmaceutical industry started in 1974 with G. D. Searle & Co. He served as Vice Chairman of ANI Pharmaceuticals, Inc., until June 19, 2014. He served as a Vice Chairman and Director of BioSante Pharmaceuticals, Inc. from January 1998 to June 2013. He had been an Independent Director at Therapix Biosciences Ltd. since December 10, 2016 until August 2020. He currently is Entrepreneur in Residence at Helix 51 and the Innovation and Research Park of Rosalind Franklin University of Medicine and Science in North Chicago, Illinois. Mr. Simes was the CEO of RestorGenex Corporation from 2014 to 2016. He served as a Director of Restorgenex Corporation from March 5, 2014 to January 8, 2016. He served as a Director of Ceregene, Inc. From 1993 to 1994, he served as Director of Savient Pharmaceuticals Inc. He served as Director of Unimed Pharmaceuticals Inc., from October 1994 to January 1997. Mr. Simes holds a B. Sc. in chemistry from Brooklyn College of the City University of New York and an M. B.A. in Marketing and Finance from New York University.

Positions